cemadotin and Melanoma

cemadotin has been researched along with Melanoma* in 1 studies

Trials

1 trial(s) available for cemadotin and Melanoma

Article	Year
Activity of the dolastatin analogue, LU103793, in malignant melanoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:4 LU103793, a synthetic analogue of dolastatin 15, showed interesting pre-clinical activity in melanoma xenografts. In this phase II multicentre trial, 80 chemotherapy-naïve patients with metastatic melanoma received a total of 218 cycles of treatment. The response rate showed one complete and three partial responses of median duration six months (range 3-9.1). Toxicity was moderate, mostly haematological (neutropenia grade 4 in 16%, grade 3 in 3%). There were no significant problems with hypertension or other non-haematological toxicities. Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Staging; Neutropenia; Oligopeptides; Treatment Outcome	2001

Article

Year

Activity of the dolastatin analogue, LU103793, in malignant melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:4

LU103793, a synthetic analogue of dolastatin 15, showed interesting pre-clinical activity in melanoma xenografts. In this phase II multicentre trial, 80 chemotherapy-naïve patients with metastatic melanoma received a total of 218 cycles of treatment. The response rate showed one complete and three partial responses of median duration six months (range 3-9.1). Toxicity was moderate, mostly haematological (neutropenia grade 4 in 16%, grade 3 in 3%). There were no significant problems with hypertension or other non-haematological toxicities.

Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Staging; Neutropenia; Oligopeptides; Treatment Outcome

2001